By Allison Gatlin – Investors.com
If there’s one overarching theme that investors in biotech stocks should pay attention to in 2023, it’s “genetic medicine, genetic medicine, genetic medicine,” says Christopher Anzalone.
Anzalone is biased, of course. He’s the chief executive of Arrowhead Pharmaceuticals (ARWR), a leader in a technology known as RNA interference, which turns off problem genes at the center of inherited diseases. But Anzalone isn’t alone in believing genetic medicine will shine in the not-too-distant future.
And many believe 2023 could be a good year for biotech in other ways, too. Though the sector is known for wild fluctuations in its stocks, a number of biotechs are starting to ride a steady course, thanks to promising new research. Along with genetic medicine, the industry is making inroads to treat Alzheimer’s disease, obesity and a host of other maladies. Some analysts expect global biotech sales overall to quadruple over the course of this decade.
